1. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
- Author
-
Fabian Frontzek, Annette M. Staiger, Myroslav Zapukhlyak, Wendan Xu, Irina Bonzheim, Vanessa Borgmann, Philip Sander, Maria Joao Baptista, Jan-Niklas Heming, Philipp Berning, Ramona Wullenkord, Tabea Erdmann, Mathias Lutz, Pia Veratti, Sophia Ehrenfeld, Kirsty Wienand, Heike Horn, John R. Goodlad, Matthew R. Wilson, Ioannis Anagnostopoulos, Mario Lamping, Eva Gonzalez-Barca, Fina Climent, Antonio Salar, Josep Castellvi, Pau Abrisqueta, Javier Menarguez, Teresa Aldamiz, Julia Richter, Wolfram Klapper, Alexandar Tzankov, Stefan Dirnhofer, Andreas Rosenwald, José Luis Mate, Gustavo Tapia, Peter Lenz, Cornelius Miething, Wolfgang Hartmann, Björn Chapuy, Falko Fend, German Ott, José-Tomas Navarro, Michael Grau, and Georg Lenz
- Subjects
Science - Abstract
Plasmablastic lymphoma (PBL) is an aggressive lymphoma subtype characterized by poor prognosis but the molecular knowledge of the disease is limited. Here, the authors perform whole exome sequencing and copy number determination of primary samples highlighting IRF4 and JAK-STAT pathways as therapeutic targets for PBL.
- Published
- 2021
- Full Text
- View/download PDF